Please provide your email address to receive an email when new articles are posted on . In the PACUBA trial, a paclitaxel-eluting balloon was associated with significantly higher primary patency at 1 ...

Dublin and Las Vegas, Medtronic plc data announced today reinforce the durability and safety of the IN.PACT(TM) Admiral(TM) drug-coated balloon (DCB) in patients with peripheral arterial disease (PAD) ...

Four-year data from the Zilver® PTX® Randomized Controlled Trial of Paclitaxel-Eluting Stents for Femoropopliteal Disease from Cook Medical presented today at the 2013 Vascular Interventional Advances ...

BLOOMINGTON, Ind.--(BUSINESS WIRE)--Cook Medical announced that a new 5 mm diameter version of Zilver ® PTX ® was approved by the FDA. It is the first 5 mm drug-eluting stent in the U.S. with lengths ...

Please provide your email address to receive an email when new articles are posted on . WASHINGTON — In the ILLUMENATE trial, both safety and effectiveness endpoints demonstrated superiority of a drug ...

LAS VEGAS, NV—Drug-coated balloons (DCBs) and unique stent platforms seem poised to supplant angioplasty as the go-to treatment for femoropopliteal disease. In late-breaking trial presentations here ...

TOKYO, April 28, 2026 /PRNewswire/ -- Cordis, a global leader in interventional cardiovascular technologies, today announces the launch and availability of the SELUTION SLR™ PTA Drug-Eluting Balloon ...

LAS VEGAS and WEBSTER, Texas, Oct. 10, 2012 /PRNewswire/ -- IDEV Technologies, Inc. (IDEV) today announced positive clinical outcomes for its SUPERB pivotal clinical trial of its SUPERA® Peripheral ...

ATLANTA -- Intravascular lithotripsy (IVL) beat percutaneous transluminal angioplasty (PTA) for keeping calcified peripheral artery lesions open at 1 year, the Disrupt PAD III trial showed.

Cordis, a global leader in interventional cardiovascular technologies, announces the launch and availability of the SELUTION SLR™ PTA Drug-Eluting Balloon for use in Japan. SELUTION SLR™ DEB is ...